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Structural analysis of peptides modified with organo-iridium 
complexes, opportunities from multi-mode fragmentation  
Christopher A. Wootton, Adam J. Millett, Andrea F. Lopez-Clavijo, Cookson K. C. Chiu, Mark P. 
Barrow, Guy J. Clarkson, Peter J. Sadler, and Peter B. O’Connor*
 
The most widely used anticancer drugs are platinum complexes, but complexes of other transition metals also show 
promise and may widen the spectrum of activity, reduce side-effects, and overcome resistance. The latter include organo-
iridium(III) ‘piano-stool’ complexes. To understand their mechanism of action, it is important to discover how they bind to 
biomolecules and how binding is affected by functionalisation of the ligands bound to iridium. We have characterised, by 
MS and MS/MS techniques, unusual adducts from reactions between 3 novel iridium(III) anti-cancer complexes each 
possessing reactive sites both at the metal (coordination by substitution of a labile chlorido ligand) and on the ligand 
(covalent bond formation involving imine formation by one or two aldehyde functions). Peptide modification by the metal 
complex had a drastic effect on both Collisonally Activated Dissociation (CAD) and Electron Capture Dissociation (ECD) 
MS/MS behaviour, tuning requirements, and fragmentation channels. CAD MS/MS was effective only when studying the 
covalent condensation products. ECD MS/MS, although hindered by electron-quenching at the Iridium complex site, was 
suitable for studying many of the species observed, locating the modification sites, and often identifying them to within a 
single amino acid residue.                                                                      .
Introduction: 
   Platinum based metallodrugs are currently used in over 50% 
of all chemotherapy. They are effective against a wide variety 
of cancers and have been studied extensively as a result, 
yielding insights into their mechanisms of action,
1
 
transformations in solution,
2
 and binding preferences with 
respect to peptides,
3
 proteins,
4
 and oligonucleotides.
5
 
Unfortunately traditional Pt
II
 drugs, including cisplatin, 
carboplatin, and oxaliplatin can cause a wide array of side 
effects and often become less effective during long term 
treatment when cancerous cells develop resistance to 
platinum.
6
  
   Other transition metals show promise as chemotherapy 
agents, some showing potencies and selectivities exceeding 
that of cisplatin.
7
 Interestingly these new transition metal 
complexes exhibit a variety of mechanisms of action.
8
 Some 
bind to DNA, causing deformations and eventually apoptosis 
(analogous to cisplatin), other metallodrugs disrupt other vital 
processes in cells in order to kill target cancer cells, including 
binding to mitochondria,
7
 or disruption of the NAD
+
/NADH 
balance inside cells.
9
 Exploring these new mechanisms of 
action against cancerous cells has become a focus for synthesis 
of the next generation of anti-cancer compounds. 
   Unlike the square planar Pt
II
 compounds, some other d-block 
metal ions readily adopt an octahedral coordination geometry. 
Pseudo-octahedral ‘piano-stool’ organo-metallic anti-cancer 
complexes can be particularly potent for a wide variety of 
metals, including: ruthenium,
10
 rhodium,
11,12
 iridium,
13,14
 and 
recently osmium.
7,15
 
 
Figure 1: Iridium(III) ‘piano-stool’ complexes used in this study. 
The C,N-chelated ligand is functionalized with one (Ir2+Cl, 
Ir3+Cl) or two (Ir1+Cl) aldehyde groups.  
 
   Here we investigate the products formed from reactions of 
three active
13
 Cp* iridium(III) complexes with the 11-residue 
peptide Substance P and the 14-residue peptide Bombesin. 
The three iridium complexes each possess two types of 
peptide binding sites: the Ir(III) itself, which possesses a labile 
monodentate chloride ligand that can be substituted by 
peptide donor atoms (e.g. thioether S of Met and imidazole N 
of His), together with aldehyde substituents on either the 
phenyl ring (complex 3), pyridyl ring (2) or both rings (1) of the 
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chelated  phenylpyridine ligand, Figure 1. The aldehyde group 
can form a covalent imine (Schiff base) adduct with an amine 
(e.g. Lys or N-terminal amino group). We sought to not only 
identify the specific sites of iridium binding to the peptides and 
the rest of the bound ligands, but also to distinguish between 
direct coordination of amino acid side-chains to Ir(III) and the 
formation of covalent bonds through condensation reactions 
involving the aldehyde functional group on the chelated 
ligand. 
 
Methylated-cyclopentadienyl iridium compounds have been 
studied previously by MS and MS/MS by Qi et.al.
14
 However, in 
the present case, a new functional group (an aldehyde) was 
introduced into the C,N-chelated ligand which allows the 
possibility of binding to potential cellular targets not only via 
the active metal centre (a common binding site for transition 
metal anticancer complexes), but also to react with the ligand 
functional groups and produce new additional covalent bonds. 
This enhanced reactivity has potential to produce interesting 
new reaction pathways and products modified by both 
covalent ligand-binding and coordination to the metal centre. 
Characterization of such products presents challenges to MS 
and especially MS/MS analysis, with the iridium complex 
having a dramatic effect on both threshold-based dissociations 
(such as CAD and IRMPD) and electron-based dissociations 
(such as ECD). 
Experimental: 
   Substance P, [Lys]3-Bombesin, and formic acid were 
purchased from Sigma Aldrich (St. Louis, MO).  LCMS grade 
Acetonitrile (ACN) was obtained from VWR (Radnor, PA) and 
used without further purification. Low concentration tuning 
mix was purchased from Agilent Technologies (Santa Clara, CA) 
and used as received. The iridium(III) anticancer complexes 
Ir2+Cl and Ir3+Cl were synthesised and characterised using 
previous methods.
13
 The synthesis of the di-aldehyde 
derivative (Ir1+Cl) is described in the Supporting Information 
(SI). 
 
Reaction of Peptides with Iridium metallodrugs: 
   Aqueous solutions of Substance P (1 mM) and [Lysine]
3
-
Bombesin (1 mM) were prepared and mixed with a solution of 
an iridium complex in ACN (250 μM) to give solutions of 0.5:1 
and 1:1 (drug:peptide) mol ratio.  The samples were then 
placed in an incubator (Genlab, Cheshire, UK) at 37 ˚C for 1-4 
days before being diluted 50-fold with ACN to MS 
concentrations (~2.5 μM summed concentration for all 
reaction products) and frozen at -80 ˚C ready for MS analysis. 
Freshly prepared samples were compared to those frozen for 1 
week to several months and showed no observable variation in 
their mass spectra. Frozen samples were thawed and placed 
on a multi vortexer (Grant Bio, Cambridge, UK) prior to MS 
analysis. No significant changes were observed for incubations 
longer than 1 day, as a result all data shown are from 1-day 
incubations. 
FT-ICR Mass spectrometry: 
   Nano-electrospray (nESI) mass spectrometry was performed 
on a Bruker SolariX Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometer (FT-ICR MS) fitted with a home-built nano 
electrospray ionisation (nESI) source and a 12 Tesla actively 
shielded magnet (Bruker Daltonics, Bremen, Germany).  
Aqueous peptide samples (5 μM) were spiked with 0.3% 
formic acid to aid effective ionisation during nESI.  Iridium-
containing samples were sprayed in ~99% ACN 1% H2O (v/v 
after dilution) with no added acid. 
   For CAD MS/MS analysis; species of interest were isolated in 
the first quadrupole and accelerated into the hexapole 
collision cell for Collisionally Activated Dissociation (CAD) at 
10-30 V and continuously accumulated for 0.1 - 4 seconds 
before transfer to the Infinity Cell for detection.
16
 
   For ECD MS/MS analysis; the species of interest were 
isolated in the first quadrupole, externally accumulated in the 
collision cell for 0.1-7 seconds and then transferred to the 
Infinity Cell for Electron Capture Dissociation (ECD) 
fragmentation and detection. Ions in the Infinity Cell were 
irradiated with 1.3 eV (peptides) - 2.5 eV (Ir adducts) electrons 
from a 1.5 A hollow cathode dispenser for 50 - 1200 ms prior 
to detection. Certain irdium-bound biomolecule species were 
also irradiated with a continuous wave IR laser (10.6 µm, 
Synrad Inc., Washington, USA) during the ECD event to aid in 
ECD fragmentation, but tuned to avoid any IR-induced 
fragmentation, spectra are marked accordingly in the SI. 
   MS/MS spectra were internally calibrated using the minimal 
number of unmodified (peptide spectra) or modified (Ir adduct 
spectra) b/c ions and the charge reduced species [M+nH]
n-1+·
 
where possible (species used for calibration are marked). All 
assignments are available in the Supporting Information, 
Tables ST2-ST13. 
Results and discussion: 
   The iridium complexes reacted readily with the Substance P 
(SubP) and [Lysine]
3
-Bombesin (L3BBS). The resulting spectra 
(Figure 2, and SI Figure SF2) show only a few species: 
unreacted Iridium complex+solvent adducts (minus the Cl 
ligand, lost during the ESI process), unreacted peptide species, 
and iridium-modified peptides. Iridium-containing species 
were readily assigned as such due to Iridium’s characteristic 
isotope pattern (Figure 2 inset).
17
 The Ir complex+Substance P 
mass spectra all showed a single iridium-containing species as 
a result of the reaction. This species corresponded to the mass 
of the iridium complex+peptide minus the mass of a water 
molecule (hereafter referred to as the condensation product, 
[SubP+Irx-H2O+H]
2+
). The amidated Substance P used in this 
study contains no amino acid group which would readily lose a 
water molecule, and no water loss, amine loss, or deamidation 
was observed for peptide-only control samples. As a result, the 
observed reaction product can arise from a condensation 
reaction with one of the aldehyde functional groups contained 
within the iridium ligand.  
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   The mass spectra from the reaction of Ir complex+L3BBS 
peptide showed similar reaction products as the Ir 
complex+Substance P reaction: unmodified complex + 
adducts, unmodified peptide species, and a condensation 
product ([Ir drug+L3BBS-H2O+H]
2+
). For Ir1, the spectra also 
showed an additional reaction product, that of a non-
condensation product, [Ir drug+L3BBS+H]
2+
, based on 
observation of both the Ir complex without the Cl ligand and 
water/solvent molecule addition, ([IrC10H15C10H6N2]
+
 and 
[IrC10H15C10H6N2+H2O]
+
, respectively, Figure 2 inset. The 
identity of the iridium complex modification for L3BBS species 
was ambiguous; even with accurate mass-mass spectrometry 
(readily achieved on the FT-ICR MS used). The two product 
species had exactly the same mass and only varied by the 
location of the H2O. Both Collisionally Activated Dissociation 
(CAD) and Electron Capture Dissociation (ECD) were conducted 
on all iridium-modified species in order to elucidate not only 
the identity of the bound iridium complex, but also to locate 
the preferential binding sites for these novel therapeutic 
agents. It is noteworthy that after a 24 hour incubation with 
the iridium complexes, Substance P peptide had reacted nearly 
completely, giving a single reaction product. Although reaction 
with L3BBS produced two distinct reaction products for each 
Iridium complex, the extent of reaction was much lower (as 
observed by the lower relative intensity of peaks in the Ir-
L3BBS spectra, Figure 2).  
 
Figure 2: (a) Reaction of Substance P with iridium complex Ir1. 
(b) Reaction of [Lys]3-Bombesin with Ir1. Insets show the 
isotopic distributions for Ir1 and Ir1+peptide complexes. 
 
Tandem MS of iridium-modified species 
   Previous studies of piano-stool iridium compounds binding to 
peptides by Qi et. al. showed that the non-aldehyde 
functionalised analogues  bind to methionine residues, and can 
be studied effectively using both CAD and ECD MS/MS.
18
 Many 
peptide and protein modifications, be they natural post 
translational modifications (PTM’s) such as phosphorylation, 
synthetic modifications, or metal-based modifications, are 
often easily lost using dissociation techniques based on slow-
heating/threshold (such as CAD), but can be retained using 
electron-based dissociation techniques such as ECD, with 
metal complex modifications being particularly susceptible to 
loss during CAD. 
8,15,19
 However, standard CAD and ECD MS/MS 
of the reaction products shown in Figure 2 provided 
interesting results and non-standard dissociation mechanisms 
compared to the unmodified peptide species, each of which 
are detailed below.  
   The reactions of iridium complexes with Substance P showed 
only one iridiated-peptide product ([Irx+SubP-H2O+H]
2+
). The 
subsequent MS/MS spectrum of the quadrupole-isolated 
species is shown in Figure 3, below for ECD of Ir1 and SF9 and 
14 for Ir2 and Ir3 respectively. 
 
Figure 3: (a) Electron capture dissociation for the 
[SubstanceP+Ir1-H2O]
2+
 condensation product. (b) Vertical 
expansion (100x) of the spectrum (a) showing low intensity 
fragments. (c) Fragmentation map summarising assigned 
fragments. Orange squares/labels indicate assigned fragments 
containing the Ir modification. 
 
   The iridium modified peptides required very different 
electron energies and pulse lengths to achieve both effective 
electron capture and ECD MS/MS compared to the 
corresponding unmodified peptide ions (~2-2.5 eV and 1.2 s vs. 
~1-1.4 eV and 0.2 s respectively), with many energies simply 
producing electron capture, but little fragmentation. In 
addition, the intensity ratio of parent ion to charge-reduced 
species was drastically different between the pure peptide and 
Ir-modified-peptide ECD spectra. For instance; Substance P 
ECD MS/MS shows very effective electron capture, resulting in 
a charge-reduced species (CRS, e.g. [SubstanceP+2H]
+.
) ~5-10% 
intensity of the parent ion ([Substance P+2H]
2+
) and good 
intensity ECD fragments (~10-25% of parent ion intensity).
20
 
For the iridium-modified Substance P, the intensity of the CRS 
compared to the 2+ parent ion was 41%, which is unusually 
high for peptide ECD MS/MS. The resulting ECD fragments 
were also of very low intensity (≤1%) compared to unmodified 
ARTICLE Analyst 
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Substance P ECD MS/MS, indicating that the iridium 
modification has a dramatic effect upon the ECD process. The 
Iridium within the complex was in the 3+ oxidation state (i.e. 
Ir
III
 with two charges neutralised via bonds to ligands (Cp*Me5
-
 
and the NC
-
 ligand), leaving the Iridium centre with an overall 
1+ charge, which explains why the addition of only a single 
proton to produce the [Peptide+Irx+H]
2+
 species was detected. 
The [Ir]
+
 centre can be easily reduced to [Ir]
0
 by electron 
capture during ECD MS/MS to produce a charge-reduced 
species in which the electron has been quenched effectively by 
the iridium centre, rather than a more typical CRS where the 
electron causes backbone/sidechain dissociation, with the 
individual fragments remaining bound together via hydrogen 
bonds/other covalent/backbone bonds.
21,22
  
   The quenching of electrons during electron-based 
dissociations has been observed before when studying 
covalently-bound heme-containing biomolecules, such as 
cytochrome c,
23
  and species with particularly high histidine 
content. The conjugated π-systems were believed to stabilise 
incoming electrons and the resulting radical species generated, 
preventing/subduing ECD/ETD fragmentation during MS/MS.
24
 
Europium-bound biomolecules and some other heavy metal 
adducts are also believed to be so-called “electron sinks” and 
quench electrons.
25
 However these effects have been 
observed only with heptadentate ligands surrounding the 
metal centre or with bare metal centres as adducts/charge 
carriers on other species and not as specific biomolecule 
modifications as observed for metal complexes. Interesting 
contributions from Asakawa et.al. have shown how the 
properties of various metals affect electron capture during 
electron transfer dissociation (ETD), and how this may be 
exploited for enhanced sequencing of target biomolecules.
26,27
  
   Despite the partial quenching of ECD electrons by iridium, 
low intensity fragments were observed in all ECD MS/MS 
spectra of Ir-containing reaction products (Figure 3+4, SI 
Figures SF5, SF7, SF15, and SF17. These fragments are 
summarised in the corresponding fragmentation maps (Figure 
3, SF6, SF7, SF13, SF15, and SF17) and SI Tables ST2, ST3, ST4, 
ST8, ST10, and ST12). For the Iridium complex-modified 
Substance P species, the data suggest a preference for lysine 
binding, accompanied by loss of a water molecule during the 
process, indicating a condensation reaction between the 
terminal primary amine on the lysine side chain and the 
aldehyde functional group present on the bidentate ligand 
within the iridium complex. The condensation reaction 
between the complex and the biomolecule results in the 
formation of an Imine, a strong covalent bond which does not 
involve the metal centre directly. Also, surprisingly, there 
seems to be no evidence of binding of Iridium to the terminal 
methionine residue of either peptide, in contrast to previous 
studies by Qi et al.,
18
 who showed that the non-aldehyde 
functionalised iridium(III) complexes  bind strongly to 
methionine residues in the calcium-binding protein 
calmodulin. The presence of the aldehyde functional group(s) 
appear to influence both the mechanism of binding (binding 
via the ligand rather than the metal centre) and the 
preferential location of binding (lysine over methionine). 
   ECD MS/MS of the Irx+L3BBS condensation products (x=1, 2, 
or 3) (Figure 4, below, and SI Figures SF5, SF7, SF15, and SF17) 
also showed an unusually high CRS relative intensity compared 
to the parent ion (~250%), showing extensive quenching of 
ECD electrons. ECD of the unmodified L3BBS was fairly typical, 
with a CRS intensity ~10-20% compared to that of the 
precursor. ECD MS/MS analysis of the iridium-modified 
peptides was hindered greatly by electron quenching at the 
iridium centre, and only a few fragments could be assigned, 
indicating Iridium binding towards the N-terminus of the 
peptide (vide infra). Fortunately due to the covalent linkage, 
CAD MS/MS was able to sequence these species effectively 
and assign binding of the complexes to the lysine of the 
peptides via an imine linkage (SI SF8, SF9, SF11, SF14, and 
SF16). 
 
Figure 4: (a) IRECD MS/MS electron capture by the [Lys]3-
Bombesin+Ir2-H2O condensation product ([L3BBS+Ir2-
H2O+H]
2+
). (b) Vertical expansion (100x) of the spectrum (a) 
showing low intensity fragments. (c) Fragmentation map 
summarising assigned fragments. Shaded squares/labels 
indicate assigned fragments containing the Ir modification. 
 
   ECD MS/MS of the non-condensation product 
([Ir2+L3BBS+H]
2+
) are shown in Figure 5 and in the SI (SF13 and 
ST8). The iridium complex bound to the peptide was shown to 
have a drastic effect on the ECD spectrum, with the main 
fragmentation pathway appearing to be electron capture at 
the iridium centre (as seen in the condensation product ECD 
spectrum).The reduction of the iridium centre by captured 
electrons caused the complex to dissociate from the 
biomolecule and produce a large peak corresponding to 
unmodified [L3BBS+H]
+.
 being a 1+ ion, the [L3BBS+H]
+
 species 
produced was not able to undergo further ECD MS/MS 
fragmentation and produce detectable fragments due to the 
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charge being neutralized upon electron capture. Although 
most of the precursor ions fragmented via loss of the Iridium 
complex modification, low intensity fragment ions were 
observed and were used to locate the modification binding 
site. The iridium complexes were shown to bind preferentially 
to the His-11 residue within L3BBS in a non-condensation (i.e. 
metal-centred) fashion via a dative covalent bond to the Ir 
centre.  
   The detection of histidine-centred binding to Ir showed a 
change in the binding preference of these functionalised 
Iridium compounds in contrast to the unfunctionalised ligand 
Iridium(III) compounds studied previously
18
 which showed a 
preference for methionine residues and for the condensation 
products described above in preference to Lysine residues. 
Many other transition metal complexes, especially those based 
upon platinum(II), have often shown a distinct preference for 
binding at sulphur-containing residues (Met, Cys
4,28,29
 In 
addition it has been reported that even some iridium(III) 
compounds also preferentially bind to methionine residues. 
However the results obtained here clearly highlight the fact 
that the behaviour and reactivity of metal-based complexes 
varies greatly depending on the metal-bound ligands and the 
available biomolecule functional groups.  
   Relatively small changes to ligand configuration/identity can 
affect the course of reactions, as shown above as the aldehyde 
functionality and not only change the mechanism of binding to 
biomolecules, but also the preferred metal binding site from 
methionine (as shown by Qi et.al.)
18
 to histidine (shown 
herein). 
   The formation of the covalent imine bond by condensation 
suggested that the iridium-peptide modification should survive 
(even partially) a threshold-based dissociation technique. CAD 
MS/MS was conducted on the condensation and non-
condensation reaction products observed in the L3BBS 
spectrum. As expected CAD of the non-condensation (Ir-
bound) product resulted in loss of the iridium modification at 
low CAD energies/voltages (~5-8V) whereas backbone 
fragmentation did not occur to a useful (sequence informative) 
extent without the use of high voltages (15-20V). CAD MS/MS 
of the L3BBS condensation products, on the other hand, was 
very successful (SI Figure SF8, SF9, SF11, SF14, and SF16). 
Though CAD caused some loss of the bidentate ligand from the 
CRS, this was a minor fragmentation pathway. The vast 
majority of peaks observed were readily assigned to 
unmodified/iridium-modified b/y fragments and side-chain 
loss ions therefrom. The CAD MS/MS provided correlating and 
complementary data to the ECD MS/MS of the condensation 
product, summarised in the fragmentation maps. The 
complexes clearly bind preferentially to the lysine residue, via 
condensation and loss of a water molecule. 
 
   Although the Ir1 complex contained two aldehyde functional 
groups within the bidentate ligand, no cross-linked, di-
condensation product was observed (i.e. a product formed 
from separate condensation reactions, one at each aldehyde 
group), even during subsequent experiments using higher 
ratios of Ir1 to peptide, nor with longer reaction times (up to 7 
days). This lack of further reaction suggests a difference in 
reactivity between the aldehyde groups on the phenyl and 
pyridine rings. Comparisons between spectra of Ir2+peptide 
and Ir3-peptide showed that regardless of which ring the 
aldehyde group is positioned; only one condensation reaction 
occurs (SF2), indicating that another factor inhibits binding 
once the first imine bond is formed – most likely steric 
hindrance from the peptide coiling around/blocking further 
access to areas of the metal complex post-imine formation.  
 
Figure 5: (a) ECD MS/MS spectrum of the [Lys]
3
-Bombesin+Ir2 
reaction product ([L3BBS+Ir2+H]
2+
). (b) Vertical expansion 
(50x) of the spectrum (a) showing low intensity fragments. (c) 
Fragmentation map summarising assigned fragments. Shaded 
squares/labels indicate assigned fragments containing the Ir 
modification. 
 
   A low intensity peak was detected in the mass spectrum of 
the Ir1+L3BBS reaction mixture corresponding to a possible 
cross-linked Ir1+peptide species ([Ir1+2xL3BBS-H2O+2H]
3+
). 
However, a peptide dimer peak ([2xL3BBS+3H]
3+
) was also 
observed – resulting from 2 peptide ions held together via 
non-covalent interactions (such as hydrogen bonds). Since 
both the peptide dimer and an Ir1-modified species containing 
two peptides were both observed, the identity of the Ir1-
modified species was ambiguous. Possible species include a 
crosslinked peptide (resulting from imine formation and Ir 
binding) or an L3BBS dimer modified at one lysine residue (as 
described above). CAD and ECD MS/MS were carried out on 
the possible dimer species. CAD MS/MS predictably caused 
dissociation of the dimer at low CAD voltages (as discussed 
above), and little information was obtained other than typical 
lysine-modified fragments (as observed in the CAD MS/MS of 
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the individual condensation products). ECD MS/MS was 
hindered greatly by electron-quenching at the iridium centre 
which resulted in very low intensity fragments and the loss of 
the iridium complex formed from the most abundant 
fragmentation channel. Few sequence-informative fragments 
were identified, but those that were, showed correlating 
information to that of the ECD MS/MS of individual modified 
peptides. The metal complex was found to bind via an imine 
linkage to the lysine residue and to the other peptide via a 
coordination bond to the histidine residue. This indicates that 
the species was in fact an iridium cross-linked reaction product 
(Figure 6, below). Similar Iridium cross-linked products were 
also observed in the Ir2+L3BBS and Ir3+L3BBS mass spectra, 
again re-enforcing that only one aldehyde group and one 
metal-centred bond are required for crosslinking using these 
iridium(III) complexes. The Substance P+Ir1/Ir2/Ir3 spectra did 
not show any evidence of iridium-cross-linking, despite the 
availability of a methionine residue and the presence of two 
reactive aldehyde groups on the Ir1 complex.  
 
Figure 6: ECD MS/MS spectrum of the [Ir1+2xL3BBS-H2O+2H]
3+
 
species (a) and corresponding fragmentation map (b) showing 
the species cross-linked via the iridium metallodrug via an 
imine linkage and an iridium co-ordination bond. 
Conclusions: 
   Aldehyde-functionalised iridium piano-stool (half-sandwich) 
Cp* compounds were shown to bind to peptides via a 
coordination bond between the iridium metal centre and 
histidine residues when available (Figure 7). CAD MS/MS 
studies of Ir-bound species resulted in loss of the metal-based 
modification and subsequent secondary fragmentation of the 
resulting unmodified peptide, losing all sequence informative-
fragments related to the location of the modification.  
Figure 7: Summary of the various metallodrug-peptide 
reaction products observed and studied using different MS/MS 
techniques, along with corresponding peptide cleavage maps. 
 
ECD MS/MS of the coordinative-covalently bound species was 
especially challenging due to the electron-quenching effect of 
the iridium based modification, but did produce fragments 
revealing the locations of the modifications. These 
functionalised iridium compounds were shown to bind to 
lysine residues within biomolecules via condensation 
reactions, creating a covalent imine linkage. CAD MS/MS of the 
imine species was very effective, with the iridium modification 
being retained in subsequent fragments and allowing 
determination of the location of the modification site. Again 
ECD MS/MS of the imine-containing species was hindered 
greatly by the electron-quenching iridium centre, but 
sequence-informative fragments were observable and in some 
cases were critical in locating and characterising Ir-based 
modifications formed by covalent modification of lysine 
residues. 
   The work reinforces the need to use complimentary MS/MS 
techniques in order to study new metallo-peptide systems 
effectively and accurately. In addition, the chemistry of 
biomolecule modifications can affect MS and MS/MS 
behaviour drastically. The mode of use of slow heating 
techniques (such as CAD) and electron-based techniques differ 
greatly, with electron-based techniques such as ECD requiring 
careful tuning of electron energies, but enabling new 
fragmentation pathways and revealing sequence information. 
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Although quenching of electrons by iridium modifications was 
encountered at many electron energies, effective ECD 
fragmentation was viable with careful tuning (<0.1 eV 
increments) and balancing of ICR cell parameters, enabling 
electron capture at other points within the modified peptide 
structures. Combinations of complementary MS/MS 
techniques are key to characterising challenging metallodrug-
peptide systems, both natural and modified. 
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